Opportunity Information: Apply for PAR 16 106
Apply for PAR 16 106
- The HHS-NIH11 in the health, income security and social services sector is offering a public funding opportunity titled "Rapid Assessment of Zika Virus (ZIKV) Complications (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.286, 93.839, 93.853, 93.855, 93.856, 93.865, 93.867,.
- This funding opportunity was created on Feb 19, 2016 and posted on Feb 19, 2016.
- Applicants must submit their applications by Apr 30, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Rapid Assessment of Zika Virus (ZIKV) Complications (R21) funding opportunity (PAR 16-106) is a National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS) discretionary grant program designed to move quickly. Its central aim is to provide an expedited research mechanism for studies that can rapidly improve understanding of Zika virus infection and, especially, the complications linked to infection. Because it uses the NIH R21 activity code, the intent is generally to support early-stage, exploratory, or high-impact projects that can produce timely findings rather than long, multi-phase research programs.
The scientific urgency behind the FOA reflects Zika virus becoming a major public health concern in the mid-2010s. ZIKV is described as a single-stranded RNA virus in the Flaviviridae family and is primarily transmitted through bites from infected Aedes mosquitoes. The announcement also highlights other clinically important transmission routes that elevate risk and complicate prevention: perinatal and in utero transmission, and sexual transmission. Although Zika was first identified in 1947, the FOA emphasizes its emergence in the Americas beginning around 2014 and the large outbreak in Brazil in 2015, which drew global attention and accelerated the need for targeted research.
A key point in the description is that most infections do not lead to severe illness in the typical sense: only about 20 percent of infected people develop clinically apparent disease, and when illness occurs it is usually self-limited. The public health alarm, however, is driven by the potential for rare but devastating outcomes. The FOA underscores the suspected association between infection during pregnancy and severe microcephaly in infants, a concern significant enough that the World Health Organization declared it a public health emergency at the time. In practice, this means the opportunity is oriented toward projects that clarify whether, how, and under what circumstances ZIKV contributes to serious congenital outcomes, and how those outcomes might be detected, prevented, or mitigated.
The announcement also calls attention to blood safety. Because the virus has been found in blood, there were growing concerns about transfusion transmission. The FOA frames this as especially important for vulnerable transfusion recipients, with particular mention of pregnant women due to the potential for severe fetal outcomes. This emphasis signals that responsive research could include rapid studies relevant to screening, risk assessment, or protective strategies connected to blood donation and transfusion practices, alongside the broader clinical and epidemiologic questions surrounding complications.
From an administrative standpoint, this is a grant opportunity (Funding Instrument Type: Grant) within the Health, Income Security and Social Services activity category and is associated with multiple CFDA numbers (93.121, 93.286, 93.839, 93.853, 93.855, 93.856, 93.865, 93.867), reflecting NIH involvement across several program areas. The award ceiling is listed as $200,000, reinforcing the small, rapid, exploratory nature of the mechanism. The opportunity was created and posted on February 19, 2016, and the listed closing date is April 30, 2019.
Eligibility is broad and includes many types of domestic organizations that might be positioned to respond quickly to an emerging infectious disease threat. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with and without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; and small businesses, plus other applicants as allowed under the FOA’s additional eligibility information. Overall, the opportunity is structured to mobilize a wide research community to deliver fast, actionable evidence on Zika complications, with particular urgency around pregnancy-related outcomes and blood transfusion risk.
Frequently Asked Questions (FAQs): Rapid Assessment of Zika Virus (ZIKV) Complications (R21) - PAR 16-106
1. What is the Rapid Assessment of Zika Virus (ZIKV) Complications (R21) opportunity (PAR 16-106)?
This is a discretionary grant program from the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). It uses the NIH R21 activity code and is designed as an expedited mechanism to support research that can quickly improve understanding of Zika virus infection, especially the complications linked to infection.
2. What is the main purpose of this funding opportunity?
The central aim is to move quickly and fund studies that can rapidly improve understanding of Zika virus infection and the complications associated with it. The focus is on timely findings rather than long, multi-phase research programs.
3. What does it mean that this is an NIH R21 mechanism?
Because it uses the NIH R21 activity code, the intent is generally to support early-stage, exploratory, or high-impact projects. The mechanism is positioned to produce timely findings rather than supporting extended, multi-phase research efforts.
4. Why was this Zika-focused research opportunity considered urgent?
The opportunity reflects the public health concern that grew in the mid-2010s, including Zika virus emergence in the Americas around 2014 and a large outbreak in Brazil in 2015. These events increased the need for targeted research into infection and complications.
5. What is Zika virus (ZIKV), as described in the opportunity?
ZIKV is described as a single-stranded RNA virus in the Flaviviridae family. While Zika was first identified in 1947, this opportunity emphasizes its later emergence as a major public health concern due to outbreaks in the Americas.
6. How is Zika virus primarily transmitted?
The opportunity states that Zika virus is primarily transmitted through bites from infected Aedes mosquitoes.
7. Are there other transmission routes highlighted in the opportunity?
Yes. The opportunity highlights clinically important additional routes: perinatal transmission, in utero transmission, and sexual transmission.
8. How common is symptomatic illness from Zika infection according to the opportunity?
The opportunity notes that only about 20 percent of infected people develop clinically apparent disease, and when illness occurs it is usually self-limited.
9. If most infections are mild or asymptomatic, why are complications a major focus?
The public health alarm described in the opportunity is driven by the potential for rare but devastating outcomes, rather than typical severe illness. The funded research is oriented toward understanding these serious complications and how they occur.
10. What pregnancy-related complication is emphasized in this funding opportunity?
The opportunity underscores a suspected association between infection during pregnancy and severe microcephaly in infants. This concern is described as significant enough that the World Health Organization declared it a public health emergency at the time.
11. What types of questions about congenital outcomes does the opportunity seek to clarify?
Based on the description, responsive projects would aim to clarify whether, how, and under what circumstances ZIKV contributes to serious congenital outcomes, and how those outcomes might be detected, prevented, or mitigated.
12. Does the opportunity mention concerns about blood safety and transfusion?
Yes. It notes that the virus has been found in blood, raising concerns about transfusion transmission.
13. Why is transfusion transmission considered particularly important in this announcement?
The opportunity frames transfusion transmission as especially important for vulnerable transfusion recipients, with particular mention of pregnant women due to the potential for severe fetal outcomes.
14. What kinds of blood safety-related studies appear responsive to this opportunity?
From the description provided, responsive research could include rapid studies relevant to screening, risk assessment, or protective strategies connected to blood donation and transfusion practices, along with broader clinical and epidemiologic questions about complications.
15. What is the funding instrument type for this opportunity?
The funding instrument type is a Grant.
16. What is the activity category associated with this opportunity?
The activity category is listed as Health, Income Security and Social Services.
17. What CFDA numbers are associated with this opportunity?
The opportunity is associated with multiple CFDA numbers: 93.121, 93.286, 93.839, 93.853, 93.855, 93.856, 93.865, and 93.867.
18. What is the award ceiling listed for this opportunity?
The award ceiling is listed as $200,000, consistent with a small, rapid, exploratory mechanism.
19. When was this opportunity created and posted?
It was created and posted on February 19, 2016.
20. What is the listed closing date for this opportunity?
The listed closing date is April 30, 2019.
21. Who is eligible to apply?
Eligibility is broad and includes many domestic organization types, including:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Other Native American tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofit organizations with 501(c)(3) status (excluding institutions of higher education in that category)
- Nonprofit organizations without 501(c)(3) status (excluding institutions of higher education in that category)
- For-profit organizations other than small businesses
- Small businesses
- Other applicants as allowed under the FOA's additional eligibility information
22. Is this opportunity limited to universities and research hospitals?
No. The eligibility list includes a wide range of entities such as local and state governments, school districts, tribal governments and organizations, nonprofits, for-profits (other than small businesses), and small businesses, in addition to public and private institutions of higher education.
23. What kind of research timeline is this opportunity designed for?
The opportunity is designed to move quickly and support rapid studies that can deliver timely, actionable evidence on Zika complications.
24. What overall public health outcomes does the opportunity aim to support?
It aims to mobilize the research community to deliver fast, actionable evidence on Zika complications, with particular urgency around pregnancy-related outcomes and blood transfusion risk.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: Strengthening a Regional Public Health Surveillance, Capacity and Laboratory Network for Central America with the Secretaria General del Sistema de la Integracion Centroamericana (SG-SICA)/Consejo de Ministros de Salud de Centroamerica (COMISCA)
Previous opportunity: Army Research Institute for the Behavioral and Social Sciences- Research Fellowship Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 106
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 106) also looked into and applied for these:
| Funding Opportunity |
|---|
| Team-Based Design in Biomedical Engineering Education (R25) Apply for PAR 16 108 Funding Number: PAR 16 108 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $40,000 |
| Spermatogenic Stem Cell Culture Systems to Preserve and Restore Reproductive Capacity in Males (R01) Apply for PAR 16 114 Funding Number: PAR 16 114 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Learning Disabilities Innovation Hubs (P20) Apply for RFA HD 17 003 Funding Number: RFA HD 17 003 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $430,000 |
| Archiving and Documenting Child Health and Human Development Data Sets (R03) Apply for PAR 16 149 Funding Number: PAR 16 149 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Animal-Assisted Interventions for Special Populations (R21) Apply for RFA HD 17 015 Funding Number: RFA HD 17 015 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Animal-Assisted Interventions for Special Populations (R03) Apply for RFA HD 17 014 Funding Number: RFA HD 17 014 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R21) Apply for PAR 16 195 Funding Number: PAR 16 195 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01) Apply for PAR 16 196 Funding Number: PAR 16 196 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R03) Apply for PAR 16 197 Funding Number: PAR 16 197 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01) Apply for PAR 16 215 Funding Number: PAR 16 215 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Outcome Measures for Use in Treatment Trials of Individuals with Intellectual and Developmental Disabilities (R01) Apply for PAR 16 216 Funding Number: PAR 16 216 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Global Network for Womens and Childrens Health Research Data Coordinating Center (U24) Apply for RFA HD 17 010 Funding Number: RFA HD 17 010 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $1,300,000 |
| Understanding STI Co-Infection In At Risk and HIV Infected Adolescents and Young Adults (R01) Apply for RFA HD 17 011 Funding Number: RFA HD 17 011 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Characterization of the Adolescent Reproductive Transition (R01) Apply for PA 16 314 Funding Number: PA 16 314 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R03) Apply for PA 16 313 Funding Number: PA 16 313 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01) Apply for PA 16 311 Funding Number: PA 16 311 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Characterization of the Adolescent Reproductive Transition (R03) Apply for PA 16 316 Funding Number: PA 16 316 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R21) Apply for PA 16 312 Funding Number: PA 16 312 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Understanding STI Co-Infection In At Risk and HIV Infected Adolescents and Young Adults (R21) Apply for RFA HD 17 012 Funding Number: RFA HD 17 012 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Characterization of the Adolescent Reproductive Transition (R21) Apply for PA 16 315 Funding Number: PA 16 315 Agency: HHS-NIH11 Category: Health, Income Security and Social Services Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 106", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.